Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gion

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
European Urology|April 15, 2000
Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenarioM Gion, R Mione, P Barioli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2002
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumoursP B Vermeulen, G Gasparini, S B Fox, et al.
Molecular Ecology Resources|September 12, 2015
High-density SNP assay development for genetic analysis in maritime pine (Pinus pinaster)C Plomion, J Bartholomé, I Lesur, et al.
The International Journal of Biological Markers|November 1, 2002
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT)A Paradiso, S Volpe, A Iacobacci, et al.
ESMO Open|November 7, 2025
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trialJ J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
ESMO Open|September 10, 2024
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trialM Vaz Batista, J M Pérez-García, P Cortez, et al.
Applied Geochemistry : Journal of the International Association of Geochemistry and Cosmochemistry|March 22, 2021
Making 'Chemical Cocktails' - Evolution of Urban Geochemical Processes across the Periodic Table of ElementsSujay S Kaushal, Kelsey L Wood, Joseph G Galella, et al.
ESMO Open|January 4, 2025
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasisR Bartsch, J M Pérez-García, J Furtner, et al.
BMC Cancer|December 3, 2022
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) studyL de la Cruz-Merino, M Gion, J Cruz, et al.
ESMO Open|May 11, 2026
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE ProjectR Sánchez-Bayona, J de Nicolás-Hernández, C Saura, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
European Urology|April 15, 2000
Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenarioM Gion, R Mione, P Barioli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2002
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumoursP B Vermeulen, G Gasparini, S B Fox, et al.
Molecular Ecology Resources|September 12, 2015
High-density SNP assay development for genetic analysis in maritime pine (Pinus pinaster)C Plomion, J Bartholomé, I Lesur, et al.
The International Journal of Biological Markers|November 1, 2002
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT)A Paradiso, S Volpe, A Iacobacci, et al.
ESMO Open|November 7, 2025
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trialJ J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
ESMO Open|September 10, 2024
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trialM Vaz Batista, J M Pérez-García, P Cortez, et al.
Applied Geochemistry : Journal of the International Association of Geochemistry and Cosmochemistry|March 22, 2021
Making 'Chemical Cocktails' - Evolution of Urban Geochemical Processes across the Periodic Table of ElementsSujay S Kaushal, Kelsey L Wood, Joseph G Galella, et al.
ESMO Open|January 4, 2025
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasisR Bartsch, J M Pérez-García, J Furtner, et al.
BMC Cancer|December 3, 2022
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) studyL de la Cruz-Merino, M Gion, J Cruz, et al.
ESMO Open|May 11, 2026
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE ProjectR Sánchez-Bayona, J de Nicolás-Hernández, C Saura, et al.
Pageof 13